{
  "schemaVersion" : 2,
  "registerId" : "F2017C00795",
  "instrumentNumber" : "53/2015",
  "citation" : "Statement of Principles concerning neoplasm of the pituitary gland No. 53 of 2015",
  "conditionName" : "neoplasm of the pituitary gland",
  "effectiveFrom" : "2015-03-30",
  "standardOfProof" : "Reasonable Hypothesis",
  "icdCodes" : [ {
    "version" : "ICD-10-AM",
    "code" : "C75.1"
  }, {
    "version" : "ICD-10-AM",
    "code" : "D35.2"
  }, {
    "version" : "ICD-10-AM",
    "code" : "D44.3"
  } ],
  "onsetFactors" : [ {
    "paragraph" : "6(a)",
    "text" : "having received a cumulative equivalent dose of at least 0.1 sievert of\r\nionising radiation to the pituitary gland at least five years before the\r\nclinical onset of neoplasm of the pituitary gland",
    "definedTerms" : [ {
      "term" : "cumulative equivalent dose",
      "definition" : "means the total dose of ionising radiation\nreceived by the particular organ or tissue from external exposure, internal\nexposure or both, apart from normal background radiation exposure in\nAustralia, calculated in accordance with the methodology set out in Guide to\ncalculation of 'cumulative equivalent dose' for the purpose of applying\nionising radiation factors contained in Statements of Principles determined\nunder Part XIA of the Veterans' Entitlements Act 1986 (Cth), Australian\nRadiation Protection and Nuclear Safety Agency, as in force on 2 August\n2017;\nNote 1: Examples of circumstances that might lead to exposure to ionising radiation include\nbeing present during or subsequent to the testing or use of nuclear weapons,\nundergoing diagnostic or therapeutic medical procedures involving ionising radiation,\nand being a member of an aircrew, leading to increased levels of exposure to cosmic\nradiation.\nNote 2: For the purpose of dose reconstruction, dose is calculated as an average over the mass\nof a specific tissue or organ. If a tissue is exposed to multiple sources of ionising\nradiation, the various dose estimates for each type of radiation must be combined"
    } ]
  } ],
  "aggravationFactors" : [ {
    "paragraph" : "6(b)",
    "text" : "for ACTH secreting pituitary adenomas only, undergoing bilateral\r\nadrenalectomy before the clinical worsening of neoplasm of the\r\npituitary gland",
    "definedTerms" : [ {
      "term" : "ACTH",
      "definition" : "means adrenocorticotrophic hormone (or corticotropin), a hormone\nsecreted by the anterior pituitary gland that stimulates the secretion of\ncorticosteroids from the adrenal cortex"
    } ],
    "conditionVariant" : {
      "name" : "ACTH secreting pituitary adenomas",
      "variantFactors" : [ ]
    }
  }, {
    "paragraph" : "6(c)",
    "text" : "inability to obtain appropriate clinical management for neoplasm of the\r\npituitary gland",
    "definedTerms" : [ ]
  } ]
}